---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-021371"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T06:46:08.468739+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elutia Q4 2024: BioEnvelope sales +18% to $2.7M; EluPro pilot launch gains traction; net loss $9.1M

## Summary
- Q4 BioEnvelope sales $2.7M (+18% YoY); overall net sales $5.5M (-7% YoY) due to SimpliDerm and cardiovascular declines.
- EluPro accounted for over 30% of BioEnvelope sales in Q4; 67 approved accounts and ~100 actively ordering.
- Q4 GAAP gross margin improved to 42.5% (from 36.2%); adjusted gross margin 58.1% (from 50.6%).
- Full year 2024 net loss from continuing ops $54.1M vs $41.2M; adjusted EBITDA loss narrowed to $12.9M from $14.4M.
- Year-end cash $13.2M; raised ~$15M gross proceeds in February 2025 registered direct offering.

## SEC filing metadata
- accession: 0001104659-25-021371
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465925021371/0001104659-25-021371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465925021371/tm258477d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-021371
- JSON: https://secwatch.observer/filing/0001104659-25-021371.json
- Plain text: https://secwatch.observer/filing/0001104659-25-021371.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.